Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome.

Hu T, Buus TB, Krejsgaard T, Nansen A, Lundholt BK, Spee P, Fredholm S, Petersen DL, Blümel E, Gluud M, Monteiro MN, Willerslev-Olsen A, Andersen MH, Straten PT, Met Ö, Stolearenco V, Fogh H, Gniadecki R, Nastasi C, Litman T, Woetmann A, Gjerdrum LMR, Ødum N.

Oncotarget. 2019 Aug 6;10(47):4894-4906. doi: 10.18632/oncotarget.27122. eCollection 2019 Aug 6.

2.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Peeters MJW, Dulkeviciute D, Draghi A, Ritter C, Rahbech A, Skadborg SK, Seremet T, Carnaz Simões AM, Martinenaite E, Halldórsdóttir HR, Andersen MH, Olofsson GH, Svane IM, Rasmussen LJ, Met Ö, Becker JC, Donia M, Desler C, Thor Straten P.

Cancer Immunol Res. 2019 Sep;7(9):1472-1484. doi: 10.1158/2326-6066.CIR-18-0841. Epub 2019 Jul 2.

PMID:
31266785
3.

[Cancer immune therapy for the treatment of haematological malignancies].

Holmström MO, Klausen U, Jørgensen NG, Holmberg S, Grauslund J, Met Ö, Svane IM, Pedersen LM, Knudsen LM, Hasselbalch HC, Andersen MH.

Ugeskr Laeger. 2019 Mar 4;181(10). pii: V06180421. Danish.

PMID:
30869069
4.

Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.

Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, Nøttrup TJ, Andersen P, Hasselager T, Met Ö, Nelson BH, Donia M, Svane IM.

Oncoimmunology. 2018 Sep 26;7(12):e1502905. doi: 10.1080/2162402X.2018.1502905. eCollection 2018.

PMID:
30524900
5.

Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.

Idorn M, Skadborg SK, Kellermann L, Halldórsdóttir HR, Holmen Olofsson G, Met Ö, Thor Straten P.

Oncoimmunology. 2018 Apr 18;7(8):e1450715. doi: 10.1080/2162402X.2018.1450715. eCollection 2018.

6.

Principles of adoptive T cell therapy in cancer.

Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM.

Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5. Review.

PMID:
30187086
7.

SATB1 in Malignant T Cells.

Fredholm S, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL, Friese C, Blümel E, Petersen DL, Hu T, Nastasi C, Lindahl LM, Buus TB, Krejsgaard T, Wasik MA, Kopp KL, Koralov SB, Persson JL, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Becker JC, Ødum N.

J Invest Dermatol. 2018 Aug;138(8):1805-1815. doi: 10.1016/j.jid.2018.03.1526. Epub 2018 May 8.

8.

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.

Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, Radic HD, Chamberlain CA, Hölmich LR, Hendel HW, Larsen MS, Met Ö, Svane IM, Donia M.

Ann Oncol. 2018 Jul 1;29(7):1575-1581. doi: 10.1093/annonc/mdy139.

PMID:
29688262
9.

Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.

Idorn M, Olsen M, Halldórsdóttir HR, Skadborg SK, Pedersen M, Høgdall C, Høgdall E, Met Ö, Thor Straten P.

Oncoimmunology. 2017 Dec 26;7(4):e1412029. doi: 10.1080/2162402X.2017.1412029. eCollection 2018.

10.

Frequent adaptive immune responses against arginase-1.

Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, Met Ö, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2017 Dec 26;7(3):e1404215. doi: 10.1080/2162402X.2017.1404215. eCollection 2018.

11.

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH.

Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018.

12.

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.

Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Met Ö, Seliger B, Kromann-Andersen B, Hasselager T, Donia M, Svane IM.

Cancer Immunol Res. 2018 Feb;6(2):222-235. doi: 10.1158/2326-6066.CIR-17-0467. Epub 2018 Jan 4.

13.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH.

Leukemia. 2018 Feb;32(2):429-437. doi: 10.1038/leu.2017.214. Epub 2017 Jul 5.

PMID:
28676668
14.

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met Ö, Hansen M, Lindberg H, Sengeløv L, Svane IM.

Cytotherapy. 2017 Apr;19(4):500-513. doi: 10.1016/j.jcyt.2017.01.007. Epub 2017 Feb 15.

PMID:
28215654
15.

CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment.

Martinenaite E, Munir Ahmad S, Hansen M, Met Ö, Westergaard MW, Larsen SK, Klausen TW, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2016 Sep 30;5(11):e1238541. doi: 10.1080/2162402X.2016.1238541. eCollection 2016.

16.

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.

Holmström MO, Hjortsø MD, Ahmad SM, Met Ö, Martinenaite E, Riley C, Straten P, Svane IM, Hasselbalch HC, Andersen MH.

Leukemia. 2017 Feb;31(2):495-498. doi: 10.1038/leu.2016.290. Epub 2016 Oct 20. No abstract available.

PMID:
27761006
17.

mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ö, Hansen M, Andersen MH, Thor Straten P, Svane IM.

Oncoimmunology. 2016 Jul 8;5(9):e1207842. eCollection 2016.

18.

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.

Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met Ö, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2016 Jul 1;5(8):e1202391. doi: 10.1080/2162402X.2016.1202391. eCollection 2016 Aug.

19.

Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21.

Hansen M, Met Ö, Larsen NB, Rosenkilde MM, Andersen MH, Svane IM, Hjortø GM.

Cytotherapy. 2016 Sep;18(9):1187-96. doi: 10.1016/j.jcyt.2016.06.010. Epub 2016 Jul 14.

PMID:
27424146
20.

Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin-Expressing Cells.

Nitschke NJ, Bjoern J, Met O, Svane IM, Andersen MH.

Scand J Immunol. 2016 Sep;84(3):191-3. doi: 10.1111/sji.12456. No abstract available.

21.

Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.

Idorn M, Thor Straten P, Svane IM, Met Ö.

Methods Mol Biol. 2016;1428:261-76. doi: 10.1007/978-1-4939-3625-0_17.

PMID:
27236805
22.

Immune Monitoring Using mRNA-Transfected Dendritic Cells.

Borch TH, Svane IM, Met Ö.

Methods Mol Biol. 2016;1428:245-59. doi: 10.1007/978-1-4939-3625-0_16.

PMID:
27236804
23.

Large-Scale mRNA Transfection of Dendritic Cells by Electroporation in Continuous Flow Systems.

Selmeczi D, Hansen TS, Met Ö, Svane IM, Larsen NB.

Methods Mol Biol. 2016;1428:151-61. doi: 10.1007/978-1-4939-3625-0_10.

PMID:
27236798
24.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH, Thor Straten P, Svane IM.

Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22.

25.

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.

Hjortsø MD, Larsen SK, Kongsted P, Met Ö, Frøsig TM, Andersen GH, Ahmad SM, Svane IM, Becker JC, Straten PT, Andersen MH.

Oncoimmunology. 2015 Jan 30;4(1):e968480. eCollection 2015 Jan.

26.

Broadening the repertoire of melanoma-associated T-cell epitopes.

Frøsig TM, Lyngaa R, Met Ö, Larsen SK, Donia M, Svane IM, Thor Straten P, Hadrup SR.

Cancer Immunol Immunother. 2015 May;64(5):609-20. doi: 10.1007/s00262-015-1664-x. Epub 2015 Feb 18.

27.

Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor.

Donia M, Larsen SM, Met O, Svane IM.

Cytotherapy. 2014 Aug;16(8):1117-20. doi: 10.1016/j.jcyt.2014.02.004. Epub 2014 May 13.

PMID:
24831841
28.

T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.

Lyngaa R, Pedersen NW, Schrama D, Thrue CA, Ibrani D, Met O, Thor Straten P, Nghiem P, Becker JC, Hadrup SR.

Clin Cancer Res. 2014 Apr 1;20(7):1768-78. doi: 10.1158/1078-0432.CCR-13-2697. Epub 2014 Feb 13.

29.

Spontaneous presence of FOXO3-specific T cells in cancer patients.

Larsen SK, Ahmad SM, Idorn M, Met Ö, Martinenaite E, Svane IM, Straten PT, Andersen MH.

Oncoimmunology. 2014 Nov 14;3(8):e953411. eCollection 2014.

30.

In-chip fabrication of free-form 3D constructs for directed cell migration analysis.

Olsen MH, Hjortø GM, Hansen M, Met Ö, Svane IM, Larsen NB.

Lab Chip. 2013 Dec 21;13(24):4800-9. doi: 10.1039/c3lc50930c.

PMID:
24153393
31.

High frequency of T cells specific for cryptic epitopes in melanoma patients.

Andersen RS, Andersen SR, Hjortsø MD, Lyngaa R, Idorn M, Køllgård TM, Met O, Thor Straten P, Hadrup SR.

Oncoimmunology. 2013 Jul 1;2(7):e25374.

32.

Silencing of the glucocorticoid-induced leucine zipper improves the immunogenicity of clinical-grade dendritic cells.

Cathelin D, Met Ö, Svane IM.

Cytotherapy. 2013 Jun;15(6):740-9. doi: 10.1016/j.jcyt.2013.02.005.

PMID:
23643305
33.

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

Munir S, Andersen GH, Met Ö, Donia M, Frøsig TM, Larsen SK, Klausen TW, Svane IM, Andersen MH.

Cancer Res. 2013 Mar 15;73(6):1764-76. doi: 10.1158/0008-5472.CAN-12-3507. Epub 2013 Jan 17.

34.

Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.

Met O, Svane IM.

Methods Mol Biol. 2013;969:275-92. doi: 10.1007/978-1-62703-260-5_17. Review.

PMID:
23296940
35.

Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.

Hansen M, Hjortø GM, Donia M, Met Ö, Larsen NB, Andersen MH, thor Straten P, Svane IM.

Vaccine. 2013 Jan 11;31(4):639-46. doi: 10.1016/j.vaccine.2012.11.053. Epub 2012 Nov 29.

PMID:
23200882
36.

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, thor Straten P, Svane IM.

J Transl Med. 2012 Aug 21;10:169. doi: 10.1186/1479-5876-10-169.

37.

Cellular based cancer vaccines: type 1 polarization of dendritic cells.

Hansen M, Met Ö, Svane IM, Andersen MH.

Curr Med Chem. 2012;19(25):4239-46. Review.

PMID:
22834814
38.

Efficient large volume electroporation of dendritic cells through micrometer scale manipulation of flow in a disposable polymer chip.

Selmeczi D, Hansen TS, Met O, Svane IM, Larsen NB.

Biomed Microdevices. 2011 Apr;13(2):383-92. doi: 10.1007/s10544-010-9507-1.

PMID:
21207149
39.

Cell culture plastics with immobilized interleukin-4 for monocyte differentiation.

Hansen M, Hjortø GM, Met O, Jakobsen MH, Svane IM, Larsen NB.

J Biomed Mater Res A. 2011 Feb;96(2):372-83. doi: 10.1002/jbm.a.32986. Epub 2010 Dec 8.

PMID:
21171157
40.

High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer.

Met O, Balslev E, Flyger H, Svane IM.

Breast Cancer Res Treat. 2011 Jan;125(2):395-406. doi: 10.1007/s10549-010-0844-9. Epub 2010 Mar 25.

PMID:
20336365
41.

Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function.

Trepiakas R, Pedersen AE, Met O, Svane IM.

Vaccine. 2009 Apr 6;27(16):2213-9. doi: 10.1016/j.vaccine.2009.02.015. Epub 2009 Feb 13.

PMID:
19428835
42.

Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.

Met O, Eriksen J, Svane IM.

Mol Biotechnol. 2008 Oct;40(2):151-60. doi: 10.1007/s12033-008-9071-6. Epub 2008 Jun 10.

PMID:
18543130
43.

Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.

Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM.

Vaccine. 2008 Jun 2;26(23):2824-32. doi: 10.1016/j.vaccine.2008.03.054. Epub 2008 Apr 11.

PMID:
18450338
44.

The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.

Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH.

Cancer Lett. 2006 Jan 18;231(2):247-56.

PMID:
16399226
45.

Immunobiological effects of glucosamine in vitro.

Forchhammer L, Thorn M, Met O, Gad M, Weidner MS, Claesson MH.

Scand J Immunol. 2003 Oct;58(4):404-11.

46.

Supplemental Content

Support Center